A drug used to treat prostate cancer that has spread to other parts of the body and is castration sensitive (has responded to treatments that lower testosterone levels) and prostate cancer that is castration resistant (has not responded to treatments that lower testosterone levels). It is also being studied in the treatment of other types of cancer. Enzalutamide binds to proteins called androgen receptors, which are found in some prostate cancer cells. These proteins bind to androgens (male hormones) and may cause cancer cells to grow. Enzalutamide blocks these proteins and may keep cancer cells from growing. It is a type of antiandrogen. Also called Xtandi. US Brand Name(s): Xtandi. FDA Approved Yes.

Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), nonmetastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer (mCSPC). It is taken by mouth.

Enzalutamide was first described in 2006, and was introduced for the treatment of prostate cancer in 2012. It was the first second-generation NSAA to be introduced. It is on the World Health Organization’s List of Essential Medicines.

Enzalutamide is approved to treat: Prostate cancer. Enzalutamide is also being studied in the treatment of other types of cancer.

A drug used alone or with other drugs under the brand name Cabometyx to treat certain types of hepatocellular carcinoma (a type of liver cancer), renal cell carcinoma (a type of kidney cancer), and differentiated thyroid cancer and under the brand name Cometriq to treat certain types of medullary thyroid cancer. Cabozantinib-s-malate is also being studied in the treatment of other types of cancer. It blocks certain proteins, which may help keep cancer cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cabozantinib-s-malate is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor.

Cabozantinib-s-malate is approved to treat:

• Differentiated thyroid cancer
• Hepatocellular carcinoma
• Medullary thyroid cancer
• Renal cell carcinoma

In November 2012, cabozantinib in its capsule formulation was approved by the U.S. Food and Drug Administration (FDA) under the name Cometriq for treating patients with medullary thyroid cancer. The capsule form was approved in the European Union for the same purpose in 2014. In April 2016, the FDA granted approval for marketing the tablet formulation (Cabometyx) as a second line treatment for kidney cancer and the same was approved in the European Union in September of that year.

A drug that binds to the protein VEGF to help keep new blood vessels from forming and is used to treat many different types of cancer. Bevacizumab is used under the brand names Alymsys, Mvasi, Avastin, and Zirabev, alone or with other drugs, to treat certain types of cervical cancer, colorectal cancer, non-small cell lung cancer, renal cell carcinoma (a type of kidney cancer), and glioblastoma (a type of brain cancer). The Alymsys and Avastin brands of bevacizumab are also used to treat certain types of ovarian epithelial, fallopian tube, and primary peritoneal cancer. The Avastin brand is also used to treat certain types of hepatocellular carcinoma (a type of liver cancer). Bevacizumab is also being studied in the treatment of other types of cancer. It may prevent the growth of new blood vessels that tumors need to grow. Bevacizumab is a type of antiangiogenesis agent and a type of monoclonal antibody. US Brand Name(s): Alymsys, Avastin, Mvasi, Zirabev. FDA Approved: Yes

Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).

Bevacizumab is approved to be used alone or with other drugs to treat:

Cervical cancer that has not gotten better with other treatment, has metastasized (spread to other parts of the body), or has recurred (come back). It is used with paclitaxel and either cisplatin or topotecan hydrochloride. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.

Colorectal cancer that has metastasized. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.

Hepatocellular carcinoma (a type of liver cancer) that is metastatic or cannot be removed by surgery. It is used with atezolizumab in patients who have not received systemic therapy. This use is approved for the Avastin brand of bevacizumab.

Nonsquamous non-small cell lung cancer that is locally advanced, cannot be removed by surgery, has metastasized, or has recurred. It is used with carboplatin and paclitaxel as first-line therapy. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.

Ovarian epithelial, fallopian tube, or primary peritoneal cancer.

Renal cell carcinoma (a type of kidney cancer) that has metastasized. It is used with interferon alpha. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.

Bevacizumab is also being studied in the treatment of other types of cancer.

A drug used to treat adults with some types of non-small cell lung cancer that have certain mutations (changes) in the EGFR gene. It is also being studied in the treatment of other types of cancer. Osimertinib mesylate blocks certain proteins made by the mutated EGFR gene, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called Tagrisso. US Brand Name(s): Tagrisso. FDA Approved Yes

Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Osimertinib was approved for medical use in the United States in November 2015, and in the European Union in February 2016.

Osimertinib mesylate is approved to treat: Non-small cell lung cancer in adults whose tumors have certain EGFR gene mutations. Osimertinib mesylate is also being studied in the treatment of other types of cancer.

A drug used to treat prostate cancer that has spread to other parts of the body and is castration sensitive (has responded to treatments that lower testosterone levels) and prostate cancer that is castration resistant (has not responded to treatments that lower testosterone levels). It is also being studied in the treatment of other types of cancer. Enzalutamide binds to proteins called androgen receptors, which are found in some prostate cancer cells. These proteins bind to androgens (male hormones) and may cause cancer cells to grow. Enzalutamide blocks these proteins and may keep cancer cells from growing. It is a type of antiandrogen. Also called Xtandi. US Brand Name(s): Xtandi. FDA Approved Yes.

Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), nonmetastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer (mCSPC). It is taken by mouth.

Enzalutamide was first described in 2006, and was introduced for the treatment of prostate cancer in 2012. It was the first second-generation NSAA to be introduced. It is on the World Health Organization’s List of Essential Medicines.

Enzalutamide is approved to treat: Prostate cancer. Enzalutamide is also being studied in the treatment of other types of cancer.

A drug used alone or with other drugs under the brand name Cabometyx to treat certain types of hepatocellular carcinoma (a type of liver cancer), renal cell carcinoma (a type of kidney cancer), and differentiated thyroid cancer and under the brand name Cometriq to treat certain types of medullary thyroid cancer. Cabozantinib-s-malate is also being studied in the treatment of other types of cancer. It blocks certain proteins, which may help keep cancer cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cabozantinib-s-malate is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor.

Cabozantinib-s-malate is approved to treat:

• Differentiated thyroid cancer
• Hepatocellular carcinoma
• Medullary thyroid cancer
• Renal cell carcinoma

In November 2012, cabozantinib in its capsule formulation was approved by the U.S. Food and Drug Administration (FDA) under the name Cometriq for treating patients with medullary thyroid cancer. The capsule form was approved in the European Union for the same purpose in 2014. In April 2016, the FDA granted approval for marketing the tablet formulation (Cabometyx) as a second line treatment for kidney cancer and the same was approved in the European Union in September of that year.

A drug that binds to the protein VEGF to help keep new blood vessels from forming and is used to treat many different types of cancer. Bevacizumab is used under the brand names Alymsys, Mvasi, Avastin, and Zirabev, alone or with other drugs, to treat certain types of cervical cancer, colorectal cancer, non-small cell lung cancer, renal cell carcinoma (a type of kidney cancer), and glioblastoma (a type of brain cancer). The Alymsys and Avastin brands of bevacizumab are also used to treat certain types of ovarian epithelial, fallopian tube, and primary peritoneal cancer. The Avastin brand is also used to treat certain types of hepatocellular carcinoma (a type of liver cancer). Bevacizumab is also being studied in the treatment of other types of cancer. It may prevent the growth of new blood vessels that tumors need to grow. Bevacizumab is a type of antiangiogenesis agent and a type of monoclonal antibody. US Brand Name(s): Alymsys, Avastin, Mvasi, Zirabev. FDA Approved: Yes

Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).

Bevacizumab is approved to be used alone or with other drugs to treat:

Cervical cancer that has not gotten better with other treatment, has metastasized (spread to other parts of the body), or has recurred (come back). It is used with paclitaxel and either cisplatin or topotecan hydrochloride. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.

Colorectal cancer that has metastasized. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.

Hepatocellular carcinoma (a type of liver cancer) that is metastatic or cannot be removed by surgery. It is used with atezolizumab in patients who have not received systemic therapy. This use is approved for the Avastin brand of bevacizumab.

Nonsquamous non-small cell lung cancer that is locally advanced, cannot be removed by surgery, has metastasized, or has recurred. It is used with carboplatin and paclitaxel as first-line therapy. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.

Ovarian epithelial, fallopian tube, or primary peritoneal cancer.

Renal cell carcinoma (a type of kidney cancer) that has metastasized. It is used with interferon alpha. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.

Bevacizumab is also being studied in the treatment of other types of cancer.

A drug used to treat adults with some types of non-small cell lung cancer that have certain mutations (changes) in the EGFR gene. It is also being studied in the treatment of other types of cancer. Osimertinib mesylate blocks certain proteins made by the mutated EGFR gene, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called Tagrisso. US Brand Name(s): Tagrisso. FDA Approved Yes

Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Osimertinib was approved for medical use in the United States in November 2015, and in the European Union in February 2016.

Osimertinib mesylate is approved to treat: Non-small cell lung cancer in adults whose tumors have certain EGFR gene mutations. Osimertinib mesylate is also being studied in the treatment of other types of cancer.